Article in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Zhiyong Yang *Department of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0000-0003-1311-4931
Yufeng Hu *Department of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0000-0002-9416-262X
Chunyong Yang *Department of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0000-0002-6848-5919
Yujie Li *Department of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0000-0003-3527-5859
Xueyuan ZhongDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0009-0002-5940-3499
Zhenfu WuDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0009-0004-8498-7881
Yingjie ZuoDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0009-0008-5454-5408
Shanyu GanDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0009-0004-3323-7941
Lin ChenDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0000-0003-0997-1869
Ziyang ZengDepartment of Anesthesiology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.ORCID 0009-0003-7807-6152
Guiheng QiDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0009-0007-7547-8593
Yuanbao ChenDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0009-0000-5849-091X
Junjie ZhouDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.ORCID 0000-0002-9588-9839
Xiao-Jing ZhangDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China yibin1974@tmmu.edu.cn lihongliang1@gmu.cn zhangxjing@whu.edu.cn.ORCID 0000-0002-8271-7405
Hongliang LiDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China yibin1974@tmmu.edu.cn lihongliang1@gmu.cn zhangxjing@whu.edu.cn.ORCID 0000-0002-9821-0297
Bin YiDepartment of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China yibin1974@tmmu.edu.cn lihongliang1@gmu.cn zhangxjing@whu.edu.cn.ORCID 0000-0001-5840-2086
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundThe JAK/STAT pathway plays a pivotal role in hepatic ischaemia/reperfusion (I/R) injury, a serious perioperative complication. Although signal transducers and activators of transcription 1 (STAT1) activation is known to drive I/R-induced injury, the specific post-translational modifications (PTMs) governing its activity in hepatic I/R remain poorly understood.
objectiveThis study identifies SMYD2, SET and MYND domain Containing 2 (SMYD2) as a critical regulator of STAT1 and investigates the mechanistic basis of SMYD2-mediated PTMs in modulating STAT1 function during hepatic I/R.
designUsing an integrated transcriptomic-proteomic approach and functional screening, we identified SMYD2 as a critical regulator of STAT1 activation in hepatic I/R injury. Clinical correlations linked SMYD2 expression to postoperative liver function, while loss-of-function and gain-of-function studies in vitro and in vivo validated its mechanistic role.
resultsOur findings demonstrate that SMYD2 modulates hepatic I/R injury through the JAK-STAT1 pathway. Clinically, elevated SMYD2 expression correlated with improved liver function and better surgical outcomes following hepatectomy. Mechanistic studies revealed that SMYD2 physically interacts with STAT1 and mediates its methylation at lysine 175 (K175), thereby inhibiting STAT1 phosphorylation and nuclear translocation. Both in vitro and in vivo studies demonstrated that SMYD2 overexpression alleviated hepatic I/R injury, whereas its genetic depletion or pharmacological inhibition exacerbated the damage.
conclusionThis study establishes SMYD2 as a novel negative regulator of STAT1 activity through K175 methylation, providing new insights into the epigenetic control of STAT1 during hepatic I/R injury. Our findings reveal a previously unrecognised mechanism for fine-tuning STAT1 signalling in hepatic I/R injury, and targeting the SMYD2-STAT1 axis may present a promising therapeutic strategy for mitigating I/R-associated liver damage.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways. · full record | OpenQuestion